...
首页> 外文期刊>Human vaccines & immunotherapeutics. >Assessment of mumps-containing vaccine effectiveness during an outbreak: Importance to introduce the 2-dose schedule for China
【24h】

Assessment of mumps-containing vaccine effectiveness during an outbreak: Importance to introduce the 2-dose schedule for China

机译:爆发期间含有含有腮腺炎的疫苗效果的评估:重要的是引入中国的2剂时

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Introduction: China has used 3 different mumps-containing vaccines (MuCV) since 1990: monovalent mumps vaccine, measles-mumps (MM) vaccine, and measles-mumps-rubella (MMR) vaccine, and one dose MuCV (using MMR at 18 months) has been included in the EPI since 2007. MuCV effectiveness has been of concern following large-scale mumps outbreaks. In 2015, an outbreak of mumps occurred in a primary school, which allow us assess vaccine effectiveness of different MuCVs.Method: All children in the school were studied as a retrospective cohort. Vaccination histories and case information were obtained from vaccination records and clinic/hospital logs. Parental questionnaires were used to confirm students' illnesses and calculate attack rate (AR). VE was assessed using the formula, VE = (AR in unvaccinated students- AR in the vaccinated students) / (AR in unvaccinated students). VEs of different type of MuCV were compared.Results: In total, 283 students were identified as clinical mumps among the 2370 students, and 1908 students were included for MuCV VE assessment. 213 (including 21 [8.9%] patients) were 2-dose MuCV recipients (AR: 9.9%), 1165 (including 123 [51.9%] patients) were 1-dose recipients (AR: 10.6%), and 530 (including 93 [39.2%] patients) were unvaccinated (AR: 17.5%). VE was 44% for 2 doses and 40% for one dose. For one-MuCV-dose students, estimated mumps VE was 63% for vaccinated within 3years (between vaccination and this outbreak); 50% for vaccinated within 3 to 5 years; and 34% for vaccinated more than 5years. Comparing VE by vaccine type and 5-year interval since vaccination, VE for MMR was 60%, which was consistently higher than VE for monovalent mumps vaccine (22%) and MM (2%).Conclusion: This outbreak was associated with low and declining 1-dose MuCV effectiveness. China's immunization program should evaluate the potential of a 2-dose MMR schedule to adequately control mumps.
机译:简介:中国自1990年以来使用了3种不同的腮腺炎疫苗(MUCV):单价腮腺炎疫苗,麻疹 - 腮腺炎(MM)疫苗和麻疹 - 腮腺炎 - 风疹(MMR)疫苗和一种剂量粘液(使用MMR在18个月时使用MMR )自2007年以来已被列入EPI。大规模腮腺炎爆发后,MUCV效力一直是关注的。 2015年,一所小学发生的腮腺炎爆发,允许美国评估不同粘液的疫苗效果。方法:学校的所有儿童都是回顾性的队列。从疫苗接种记录和诊所/医院原木获得疫苗接种历史和案例信息。父母调查问卷用于确认学生的疾病并计算攻击率(AR)。使用公式评估,ve =(在疫苗的学生中的未接种寄存在疫苗的学生中的ar)/(在未接待的学生中的ar中)。比较了不同类型的mucv。结果:总共有283名学生被确定为2370名学生中的临床腮腺癌,而1908名学生被列入MUCV VE评估。 213(包括21例[8.9%]患者)是2剂MUCV受体(Ar:9.9%),1165(包括123例[51.9%]患者)是1剂受者(Ar:10.6%)和530(包括93个[39.2%]患者)未被解雇(AR:17.5%)。对于2剂量为44%,一剂为40%。对于单药剂的学生,估计的腮腺炎患者在3年内接种63%(疫苗接种和这种爆发之间); 50%的疫苗接种3至5年; 34%的疫苗接种超过5年。通过疫苗类型和5年间隔进行比较,因为疫苗接种,MMR的50%是60%,这始终高于一价腮腺炎疫苗(22%)和mm(2%)。结论:这种爆发与低电平有关减少1剂MUCV效果。中国的免疫计划应评估2剂MMR时间表的潜力,以充分控制腮腺炎。

著录项

  • 来源
  • 作者单位

    Chinese Ctr Dis Control &

    Prevent Dept Natl Immunizat Program Beijing Peoples R China;

    Hangzhou Ctr Dis Control &

    Prevent Dept Expanded Program Immunizat Hangzhou Zhejiang Peoples R;

    Anhui Ctr Dis Control &

    Prevent Dept Expanded Program Immunizat Hefei Anhui Peoples R China;

    Chinese Ctr Dis Control &

    Prevent Chinese Epidemiol Training Program Beijing Peoples R China;

    Luan Ctr Dis Control &

    Prevent Dept Expanded Program Immunizat Luan Peoples R China;

    Anhui Ctr Dis Control &

    Prevent Dept Expanded Program Immunizat Hefei Anhui Peoples R China;

    Chinese Ctr Dis Control &

    Prevent Dept Natl Immunizat Program Beijing Peoples R China;

    Chinese Ctr Dis Control &

    Prevent Dept Natl Immunizat Program Beijing Peoples R China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 医学免疫学;
  • 关键词

    Mumps; vaccine; effectiveness; schedule; China;

    机译:腮腺炎;疫苗;有效性;时间表;中国;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号